ArticleBMC gastroenterology2026
Effect of concomitant chemotherapy on edoxaban plasma concentration in patients with colorectal cancer.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDirect oral anticoagulants are a treatment option for cancer-associated venous thromboembolism (VTE). In patients receiving chemotherapy for cancer, there may be pharmacokinetic drug-drug interaction between anti-cancer agents and direct oral anticoagulants. However, there are no data available in patients with colorectal cancer (CRC). In this study, we investigated edoxaban plasma concentration in patients with CRC receiving chemotherapy.
methodsThe study included patients with unresectable or metastatic CRC undergoing systemic chemotherapy and simultaneously receiving anticoagulant therapy with edoxaban for VTE or atrial fibrillation. Blood sampling was performed prior to chemotherapy and after 24 h and 48 h depending on the chemotherapy regimen.
resultsData of 21 and 26 patients were analyzed for edoxaban plasma concentration and safety, respectively. Edoxaban plasma concentration was not statistically different before and after 24 h and 48 h between patients receiving treatment with a chemotherapy regimen, cytotoxic drug, and a molecular targeted drug. One patient had major bleeding requiring transfusion; however, edoxaban plasma concentration was not elevated before and 24 h after chemotherapy (19.98 and 9.63 ng/ml, respectively).
conclusionIn patients with CRC, edoxaban plasma concentration did not change after chemotherapy, implying that drug-drug interaction between edoxaban and anti-cancer agents was minimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.